JP2022505597A5 - - Google Patents

Info

Publication number
JP2022505597A5
JP2022505597A5 JP2021521995A JP2021521995A JP2022505597A5 JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5
Authority
JP
Japan
Application number
JP2021521995A
Other languages
Japanese (ja)
Other versions
JPWO2020084480A5 (https=
JP7500555B2 (ja
JP2022505597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059004 external-priority patent/WO2020084480A1/en
Publication of JP2022505597A publication Critical patent/JP2022505597A/ja
Publication of JPWO2020084480A5 publication Critical patent/JPWO2020084480A5/ja
Publication of JP2022505597A5 publication Critical patent/JP2022505597A5/ja
Application granted granted Critical
Publication of JP7500555B2 publication Critical patent/JP7500555B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521995A 2018-10-25 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7500555B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862750395P 2018-10-25 2018-10-25
US62/750,395 2018-10-25
PCT/IB2019/059004 WO2020084480A1 (en) 2018-10-25 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (4)

Publication Number Publication Date
JP2022505597A JP2022505597A (ja) 2022-01-14
JPWO2020084480A5 JPWO2020084480A5 (https=) 2022-10-11
JP2022505597A5 true JP2022505597A5 (https=) 2022-10-11
JP7500555B2 JP7500555B2 (ja) 2024-06-17

Family

ID=68344929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521995A Active JP7500555B2 (ja) 2018-10-25 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (6)

Country Link
US (1) US20210393633A1 (https=)
EP (1) EP3870575B1 (https=)
JP (1) JP7500555B2 (https=)
ES (1) ES2942998T3 (https=)
PT (1) PT3870575T (https=)
WO (1) WO2020084480A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US20210395262A1 (en) * 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (en) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
EP3962603A1 (en) * 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR20220066922A (ko) * 2019-09-20 2022-05-24 아이디어야 바이오사이언시스 인코포레이티드 Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
US20210379071A1 (en) * 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
BR112021017339A2 (https=)
BR112021018450A2 (https=)
JP2022505597A5 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
JP2022505637A5 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021016996A2 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021018102A2 (https=)
BR112021017234A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021013128A2 (https=)
BR112021018484A2 (https=)
BR112021017949A2 (https=)
BR112021018084A2 (https=)